Menu
Home
Company
About Us
Leadership
Board of Directors
Subsidiaries
Asterias Biotherapeutics, Inc.
OncoCyte Corporation
AgeX Therapeutics
Careers
Other
Patent Portfolio
Glossary
Videos
Update Series
Investor & Corporate Updates
Science & Technologies
Products & Pipeline
Aesthetics / Renevia
®
Ophthalmics / OpRegen
®
Other
mHealth
Research Products
PureStem
®
Progenitors
Technologies
PureStem
®
Progenitors
HyStem
®
Hydrogels
Regenerative Medicine
Scientific Publications
Investors & Media
Press Releases
Biotime
Subsidiaries
Events & Presentations
Corporate Governance
Analyst Coverage
Stock Information
Financials & Filings
E-mail Alerts
Contact IR
Contact Us
Search
SEC Filings
Form 10-Q
BIOTIME INC filed this
Form 10-Q
on 11/08/2018
Document Outline
Entire Document (2965.6 KB)
Subdocument 1 - 10-Q
Page 1 - UNITED STATES
Page 2 - PART 1 FINANCIAL INFORMATION
Page 3 - BIOTIME, INC. AND SUBSIDIARIES
Page 4 - BIOTIME, INC. AND SUBSIDIARIES
Page 5 - BIOTIME, INC. AND SUBSIDIARIES
Page 6 - BIOTIME, INC. AND SUBSIDIARIES
Page 7 - BIOTIME, INC. AND SUBSIDIARIES
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - Company and Business Overview
Page 30 - Critical Accounting Policies
Page 31 - N/A
Page 32 - N/A
Page 33 - Results of Operations
Page 34 - N/A
Page 35 - N/A
Page 36 - N/A
Page 37 - N/A
Page 38 - N/A
Page 39 - N/A
Page 40 - Liquidity and Capital Resources
Page 41 - Cash flows used in operating activities
Page 42 - N/A
Page 43 - PART II - OTHER INFORMATION
Page 44 - If we or our subsidiaries issue additional common shares or preferred shares, investors in our commo
Page 45 - Failure to successfully combine the businesses of BioTime and Asterias in the expected time frame ma
Page 46 - If the conditions to the merger are not met, the merger may not occur.
Page 47 - Our ability to use our net operating loss carryforwards (NOLs) may be limited.
Page 48 - N/A
Page 49 - SIGNATURES
Page 50 - N/A
Subdocument 2 - EX-31 - Certifications required under Section 302 of the Sarbanes-Oxley Act of 2002
Page 1 - Exhibit 31
Page 2 - Exhibit 31
Page 3 - N/A
Subdocument 3 - EX-32 - Certifications required under Section 906 of the Sarbanes-Oxley Act of 2002
Page 1 - Exhibit 32
Page 2 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE FILE
(
What's this?
)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE
(
What's this?
)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE
(
What's this?
)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE
(
What's this?
)
XBRL Item - EX-101.LAB - XBRL LABEL FILE
(
What's this?
)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE
(
What's this?
)
XBRL Viewer